Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
Choosing between equal and cap weight depends on goals and risk tolerance. This quick guide compares the two for retirement suitability.
24,468 articlesAs large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
In the first half of 2026, here's plug power stock surged 37.6%, signaling a renewed optimism around hydrogen fuels a...
Two power players, two paths: Constellation Energy and Vistra offer differing mixes of stability and upside. This gui...
Peloton and Uber represent two digitally enabled businesses with very different paths. This guide breaks down the num...
Greg Abel’s early moves at Berkshire Hathaway hint at a new rhythm for the conglomerate. This article breaks down wha...
The standard Medicare Part B premium surpassed $200 per month in 2026, up $17.90 from 2025. With COLA growth lagging ...
With the Social Security trust fund projected to run dry by the early 2030s, Congress faces a high-stakes fight over ...
As rates move and markets shift in 2026, investors weigh three paths to generate $18,000 a year from a $1,500-a-month...
A simple, durable approach to building income: three passive income ETFs worth holding for the long haul. Learn how t...
When the carradine family breaks hollywood, they show how openness can shape finances and future planning. This artic...
A Tuesday uptick in Edgewise Therapeutics stock topped the market, driven by an upbeat price target from a major bank...
Singapore's companies dominate the Southeast Asia 500 by revenue, capturing roughly a third of the region's total. Th...